Please provide your email address to receive an email when new articles are posted on . IVUS may improve care of patients undergoing peripheral revascularization. More data are needed to document ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of patients with renal impairment who underwent peripheral revascularization, rivaroxaban reduced ...

Compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with lower risks of cardiac death and composite renal outcomes without ...

Treatment with rivaroxaban plus aspirin significantly reduced the risk of major adverse limb and cardiovascular events in the VOYAGER PAD study. A supplemental New Drug Application (sNDA) for ...

WASHINGTON, DC—Vascular interventions in patients with PAD are associated with comparable short-term outcomes no matter whether they’re performed via radial or femoral access, according to early ...

Compared with white patients, Black patients with PAD who undergo peripheral revascularization have much more advanced disease at the time of their procedures and are less likely to receive necessary ...

Things seem to be looking up for the field of endovascular revascularization for symptomatic peripheral artery disease (PAD), researchers suggested. Paclitaxel-coated devices were safe for patients ...

Concept Medical Inc. announced the presentation of primary results of the SirPAD randomized controlled trial of the company’ ...